Company Profile

Everist Genomics (AKA: Genetics Squared Inc)
Profile last edited on: 4/8/19      CAGE: 47GU7      UEI:

Business Identifier: Genetic programming and molecular prognostics
Year Founded
2002
First Award
2008
Latest Award
2008
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

455 East Eisenhower Parkway Suite 200
Ann Arbor, MI 48108
Location: Single
Congr. District: 12
County: Washtenaw

Public Profile

A prognostics company, Genetics Squared Inc had been organized originally around development of gene-based molecular assays for the prediction of cancer recurrence: molecular diagnostic tests especially well suited for clinical oncology though also applied in other areas of clinical and preclinical biomedical research, such as infectious disease, nephrology, and autoimmune disease, In January 2011, the firm announced name change to Everist Genomics conicident with launch its first prognostic gene-based laboratory test—OncoDefender™-CRC—intended to help guide treatment decisions following surgery for Stage I/II colon cancer and Stage I rectal cancer. In June 2013, the firm again renamed itself - this time to Everist Health Inc. with a shift towards development and commercialization of diagnostic and prognostic tests that help patients and their physicians to manage their personal health. With a worldwide presence now in many countries, product offerings include AngioDefender system, a non-invasive device to assess the presence of early-stage cardiovascular diseases and atherosclerosis; and a Vascular Age Calculator to determine the vascular age of the indivi

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2008 1 NIH $162,300
Project Title: Genetic Programming To Predict Clinical Outcome From Transcript Quantification

Key People / Management

  Matt Bartlam -- Chief Executive Officer

  William P Worzel -- Founder, CTO and former President

  Steve Everist -- CTO & Director

  Sunita Gohrani -- Chief Executive Officer of Asia

  Peter F Lenehan -- Chief Medical Officer

  Prasad Sunkara -- President

Company News

There are no news available.